Key result
Carotid intima-media thickness progression meets the criteria of a surrogate for cardiovascular disease endpoints and may be considered a valid alternative for cardiovascular events as an outcome.
Why the study?
Is carotid intima-media thickness (CIMT) a valid surrogate marker for cardiovascular disease endpoints?
Design
Review
Authors
Loading...
CIMT progression qualifies as surrogate endpoint; leaves open correlation with clinical risk changes before practice adoption.
CIMT progression is a valid surrogate marker for cardiovascular disease endpoints, though more data is needed on how changes in CIMT correlate with changes in clinical risk.
Peters et al. (2011) conducted a review in Cardiovascular disease. Carotid intima-media thickness (CIMT) was evaluated on Validity as a surrogate marker for cardiovascular events. Carotid intima-media thickness progression meets the criteria of a surrogate for cardiovascular disease endpoints and may be considered a valid alternative for cardiovascular events as an outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: